Deakin University
Browse

File(s) stored somewhere else

Please note: Linked content is NOT stored on Deakin University and we can't guarantee its availability, quality, security or accept any liability.

Continuing or ceasing bevacizumab at disease progression: Results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma.

Version 2 2024-06-06, 05:21
Version 1 2023-06-07, 01:47
conference contribution
posted on 2024-06-06, 05:21 authored by Elizabeth J Hovey, Kathryn Maree Field, Mark Rosenthal, Anna K Nowak, Lawrence Cher, Helen Wheeler, Elizabeth Barnes, Pramit Phal, Ann LivingstoneAnn Livingstone, Kate Sawkins, John Simes
Continuing or ceasing bevacizumab at disease progression: Results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma.

History

Journal

Journal of Clinical Oncology

Volume

33

Pagination

2003-2003

Location

IL, Chicago

ISSN

0732-183X

eISSN

1527-7755

Language

en

Publication classification

E3.1 Extract of paper

Title of proceedings

Journal of Clinical Oncology

Issue

15_suppl

Publisher

American Society of Clinical Oncology (ASCO)

Usage metrics

    Research Publications

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC